Rapid and consistent in-vivo drug dissolution is critical for drug absorption. However, in-vitro dissolution results do not always correlate with the in-vivo behavior of drug products. Tablets and capsules can have very different profiles, depending on their composition and processing conditions. In a recent human in-vivo study, an IR tablet formulation containing three drugs with different solubility profiles was encapsulated in either a hard gelatin or HPMC capsule. Download this whitepaper to read how the dissolution rate impacts on the bioequivalence of the formulation.
- Fast track formulation development thanks to novel Intrinsically Enteric Capsule Technology
- Early development screening for technology selection and formulation design
- Next Generation HPMC Capsules: Bioequivalence and Functional Performance
- Product Development Using the NDA 505(b)(2) Approval Pathway